Celularity, trading under the ticker CELU, has successfully addressed its listing compliance issue with Nasdaq by settling an overdue fee. The biotechnology company faced a potential delisting after Nasdaq's notification regarding a $70,000 unpaid fee, as mandated by Listing Rule 5250(f). This situation has been resolved promptly, with Celularity paying the outstanding amount in full on April 25.
By taking this decisive action, the company has secured its position on the Nasdaq exchange, alleviating concerns over its continued listing. Investors and stakeholders can now expect continued trading of Celularity shares without further interruption due to this matter.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Celularity Inc (CELU, Financial) is $8.75 with a high estimate of $15.00 and a low estimate of $2.50. The average target implies an upside of 443.48% from the current price of $1.61. More detailed estimate data can be found on the Celularity Inc (CELU) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Celularity Inc's (CELU, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Celularity Inc (CELU, Financial) in one year is $16.52, suggesting a upside of 926.09% from the current price of $1.61. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Celularity Inc (CELU) Summary page.
